Srinivas Pittala
About Srinivas Pittala
Srinivas Pittala is a Postdoctoral Fellow currently working at the National Heart, Lung, and Blood Institute in Bethesda, Maryland. He has extensive experience in pharmacological research and molecular biology, with a strong background in various animal models and regulatory guidelines.
Current Position at National Institutes of Health
Srinivas Pittala is currently employed as a Postdoctoral Fellow at the National Institutes of Health (NIH) in Bethesda, Maryland, United States. He has held this position since 2019, contributing to research initiatives within the organization. His work at NIH focuses on advancing knowledge in the fields of molecular biology and pharmacology.
Previous Experience at Ben Gurion University of the Negev
Prior to his current role, Srinivas Pittala worked at Ben Gurion University of the Negev as a Postdoctoral Research Fellow for five months in 2019. He also completed his Ph.D. at the same institution from 2015 to 2019, where he studied Biology and Philosophy, earning a Doctor of Philosophy degree.
Work Experience at IGIB and Syngene International Limited
Srinivas Pittala served as a Project Fellow at the Institute of Genomics and Integrative Biology (IGIB) in Delhi, India, from 2013 to 2015. He also gained experience as a Research Trainee in Pharmacology at Syngene International Limited in Bengaluru, India, for six months in 2013. These roles contributed to his foundational knowledge in pharmacological research.
Educational Background and Qualifications
Srinivas Pittala has a comprehensive educational background in pharmacy and related fields. He earned a Bachelor of Pharmacy from Kakatiya University from 2007 to 2010, followed by a Master of Science in Toxicology and Pharmacology from the National Institute of Pharmaceutical Education and Research from 2010 to 2012. His academic journey culminated in a Doctorate from Ben Gurion University of the Negev.
Research Expertise and Specializations
Srinivas Pittala demonstrates proficiency in molecular biology methods and has extensive experience in pharmacological screening of new chemical entities (NCEs) using various animal models. He possesses specialized knowledge in handling non-alcoholic fatty liver disease (NAFLD) and liver cancer mice models. Additionally, he is well-versed in CPCSEA guidelines, ICH_GCP guidelines, and pharma regulatory guidelines.